Drug Profile

HuL 217

Alternative Names: HuL-217

Latest Information Update: 14 Feb 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator HuniLife Biotechnology
Class Antifibrotics; Monoclonal antibodies
Mechanism of Action ENO1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Idiopathic pulmonary fibrosis

Most Recent Events

10 Feb 2022 HuL 217 is available for licensing as of 10 Feb 2022. http://en.hunilife.com/about
05 Sep 2021 Preclinical trials in Idiopathic pulmonary fibrosis in Taiwan (IV) before September 2021
05 Sep 2021 Pharmacodynamics data from a preclinical studies in Idiopathic pulmonary fibrosis presented at the 31st Annual Congress of the European Respiratory Society (ERS-2021)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com